Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.

Garrido G, Schrand B, Rabasa A, Levay A, D'Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, Dudeja V, van Hall T, Gilboa E.

Nat Commun. 2019 Aug 21;10(1):3773. doi: 10.1038/s41467-019-11728-2.

2.

Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.

Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB.

J Clin Invest. 2019 Jan 2;129(1):137-149. doi: 10.1172/JCI121266. Epub 2018 Nov 19.

3.

An RNA toolbox for cancer immunotherapy.

Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I.

Nat Rev Drug Discov. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Review.

PMID:
30190565
4.

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.

Schrand B, Clark E, Levay A, Capote AR, Martinez O, Brenneman R, Castro I, Gilboa E.

Nat Commun. 2018 Aug 22;9(1):3348. doi: 10.1038/s41467-018-05566-x.

5.

NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12.

Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O, Ban Y, Lavania S, Dawra R, Banerjee S, Vickers S, Merchant NB, Chen SX, Gilboa E, Ramakrishnan S, Saluja A, Dudeja V.

Gastroenterology. 2018 Sep;155(3):880-891.e8. doi: 10.1053/j.gastro.2018.05.051. Epub 2018 Jul 29.

6.

Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.

Puplampu-Dove Y, Gefen T, Rajagopalan A, Muheramagic D, Schrand B, Gilboa E.

Oncoimmunology. 2018 Feb 15;7(4):e1349588. doi: 10.1080/2162402X.2017.1349588. eCollection 2018.

7.

A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.

Gefen T, Castro I, Muharemagic D, Puplampu-Dove Y, Patel S, Gilboa E.

Mol Ther. 2017 Oct 4;25(10):2280-2288. doi: 10.1016/j.ymthe.2017.06.023. Epub 2017 Aug 8.

8.

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Rajagopalan A, Berezhnoy A, Schrand B, Puplampu-Dove Y, Gilboa E.

Mol Ther. 2017 Jan 4;25(1):54-61. doi: 10.1016/j.ymthe.2016.10.021. Epub 2017 Jan 4.

9.

Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.

Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A.

Cancer Res. 2017 Mar 15;77(6):1310-1321. doi: 10.1158/0008-5472.CAN-16-2105. Epub 2017 Jan 12.

10.

A quantum leap in cancer vaccines?

Gilboa E.

J Immunother Cancer. 2016 Dec 20;4:87. doi: 10.1186/s40425-016-0192-3. eCollection 2016. No abstract available.

11.

Adaptive smoothing based on Gaussian processes regression increases the sensitivity and specificity of fMRI data.

Strappini F, Gilboa E, Pitzalis S, Kay K, McAvoy M, Nehorai A, Snyder AZ.

Hum Brain Mapp. 2017 Mar;38(3):1438-1459. doi: 10.1002/hbm.23464. Epub 2016 Dec 10.

PMID:
27943516
12.

4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models.

Benaduce AP, Brenneman R, Schrand B, Pollack A, Gilboa E, Ishkanian A.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):458-461. doi: 10.1016/j.ijrobp.2016.05.013. Epub 2016 May 21.

PMID:
27598810
13.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

14.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
15.

Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.

Gilboa E, Berezhnoy A, Schrand B.

Cancer Immunol Res. 2015 Nov;3(11):1195-200. doi: 10.1158/2326-6066.CIR-15-0194. Review.

16.

Scaling Multidimensional Inference for Structured Gaussian Processes.

Gilboa E, Saatçi Y, Cunningham JP.

IEEE Trans Pattern Anal Mach Intell. 2015 Feb;37(2):424-36. doi: 10.1109/TPAMI.2013.192.

PMID:
26353252
17.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

18.

Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates.

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Gilboa E.

Oncoimmunology. 2015 Jan 9;4(3):e970918. eCollection 2015 Mar.

19.

Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery.

Hoinka J, Berezhnoy A, Dao P, Sauna ZE, Gilboa E, Przytycka TM.

Nucleic Acids Res. 2015 Jul 13;43(12):5699-707. doi: 10.1093/nar/gkv308. Epub 2015 Apr 13.

20.

CORRIGENDUM: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells.

Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY.

Sci Rep. 2015 Jan 27;5:7967. doi: 10.1038/srep07967. No abstract available.

21.

AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from its Application.

Hoinka J, Berezhnoy A, Sauna ZE, Gilboa E, Przytycka TM.

Res Comput Mol Biol. 2014;8394:115-128.

22.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

23.

Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells.

Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY.

Sci Rep. 2014 Dec 9;4:7392. doi: 10.1038/srep07392. Erratum in: Sci Rep. 2015;5:7967.

24.

A clinically useful approach to enhance immunological memory and antitumor immunity.

Berezhnoy A, Rajagopalan A, Gilboa E.

Oncoimmunology. 2014 May 14;3:e28811. eCollection 2014.

25.

Image interpolation and denoising for division of focal plane sensors using Gaussian processes.

Gilboa E, Cunningham JP, Nehorai A, Gruev V.

Opt Express. 2014 Jun 16;22(12):15277-91. doi: 10.1364/OE.22.015277.

PMID:
24977618
26.

Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E.

Cancer Immunol Res. 2014 Sep;2(9):867-77. doi: 10.1158/2326-6066.CIR-14-0007. Epub 2014 Jun 17.

27.

Controlled release of analgesic drugs from porous bioresorbable structures for various biomedical applications.

Shemesh M, Gilboa E, Ben-Gal TS, Zilberman M.

J Biomater Sci Polym Ed. 2014;25(4):410-30. doi: 10.1080/09205063.2013.863748. Epub 2013 Dec 9.

PMID:
24313726
28.

Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E.

J Clin Invest. 2014 Jan;124(1):188-97.

29.

Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay.

Gilboa E.

Immunol Res. 2013 Dec;57(1-3):44-51. doi: 10.1007/s12026-013-8442-7. Review.

PMID:
24198064
30.

CD28 aptamers as powerful immune response modulators.

Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M.

Mol Ther Nucleic Acids. 2013 Jun 11;2:e98. doi: 10.1038/mtna.2013.26.

31.

Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.

Gilboa E, McNamara J 2nd, Pastor F.

Clin Cancer Res. 2013 Mar 1;19(5):1054-62. doi: 10.1158/1078-0432.CCR-12-2067.

32.

Estimating electrical conductivity tensors of biological tissues using microelectrode arrays.

Gilboa E, La Rosa PS, Nehorai A.

Conf Proc IEEE Eng Med Biol Soc. 2012;2012:1040-4. doi: 10.1109/EMBC.2012.6346112.

PMID:
23366073
33.

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition.

Berezhnoy A, Brenneman R, Bajgelman M, Seales D, Gilboa E.

Mol Ther Nucleic Acids. 2012 Oct 16;1:e51. doi: 10.1038/mtna.2012.41.

34.

Estimating electrical conductivity tensors of biological tissues using microelectrode arrays.

Gilboa E, La Rosa PS, Nehorai A.

Ann Biomed Eng. 2012 Oct;40(10):2140-55. doi: 10.1007/s10439-012-0581-9. Epub 2012 May 12.

PMID:
22581477
35.

mRNA leapfrogs DNA to show promise for therapeutic gene transfer.

Gilboa E.

Mol Ther. 2012 Apr;20(4):694-5. doi: 10.1038/mt.2012.31. No abstract available.

36.

Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing.

Berezhnoy A, Stewart CA, Mcnamara JO 2nd, Thiel W, Giangrande P, Trinchieri G, Gilboa E.

Mol Ther. 2012 Jun;20(6):1242-50. doi: 10.1038/mt.2012.18. Epub 2012 Mar 20.

37.

The determinants of tumour immunogenicity.

Blankenstein T, Coulie PG, Gilboa E, Jaffee EM.

Nat Rev Cancer. 2012 Mar 1;12(4):307-13. doi: 10.1038/nrc3246. Review.

38.

Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.

Pastor F, Kolonias D, McNamara JO 2nd, Gilboa E.

Mol Ther. 2011 Oct;19(10):1878-86. doi: 10.1038/mt.2011.145. Epub 2011 Aug 9.

39.

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay.

Pastor F, Kolonias D, Giangrande PH, Gilboa E.

Nature. 2010 May 13;465(7295):227-30. doi: 10.1038/nature08999.

40.

Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis.

van Es T, van Puijvelde GH, Foks AC, Habets KL, Bot I, Gilboa E, Van Berkel TJ, Kuiper J.

Atherosclerosis. 2010 Mar;209(1):74-80. doi: 10.1016/j.atherosclerosis.2009.08.041. Epub 2009 Aug 31.

PMID:
19765709
41.

A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling.

Zhou J, Soontornworajit B, Martin J, Sullenger BA, Gilboa E, Wang Y.

Macromol Biosci. 2009 Sep 9;9(9):831-5. doi: 10.1002/mabi.200900046.

PMID:
19434675
42.

Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.

Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, Sullenger BA.

Chem Biol. 2008 Jul 21;15(7):675-82. doi: 10.1016/j.chembiol.2008.05.016.

43.

Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E.

J Clin Invest. 2008 Jan;118(1):376-86.

44.

Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag.

Melhem NM, Liu XD, Boczkowski D, Gilboa E, Barratt-Boyes SM.

Eur J Immunol. 2007 Aug;37(8):2164-73.

45.

DC-based cancer vaccines.

Gilboa E.

J Clin Invest. 2007 May;117(5):1195-203. Review.

46.

Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.

Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E.

Cancer Res. 2007 Jan 1;67(1):371-80.

47.

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305.

48.

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH.

Nat Biotechnol. 2006 Aug;24(8):1005-15. Epub 2006 Jun 25.

PMID:
16823371
49.

Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.

Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E.

Cancer Res. 2005 Dec 1;65(23):11156-63.

50.

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J.

J Clin Invest. 2005 Dec;115(12):3623-33. Epub 2005 Nov 23.

Supplemental Content

Loading ...
Support Center